Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recent developments in myelodysplastic syndromes

    ... (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald ...

    Research Article last updated 04/29/2016 - 11:34am.

  2. Myelodysplastic syndromes: Contemporary review and how we treat

    ... the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, ...

    Research Article last updated 04/29/2016 - 1:05pm.

  3. Phase I, Dose Escalation Study of Decitabine

    ... Purpose:  Decitabine is a hypomethylating agent that has shown significant ... Leukemia (AML). This study is based on the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  4. Personalized medicine for MDS

    ... agents, such as azacitidine and decitabine , are standard care for older patients with higher-risk MDS who ...

    Research Review last updated 05/02/2016 - 9:44am.

  5. Acute Myeloid Leukemia (AML)

    ... able to tolerate toxic chemotherapy drugs. Drugs such as decitabine or azacitidine or hydroxyurea may be better tolerated by ...

    Topic section last updated 07/07/2016 - 3:15pm.

  6. Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    ... to test the safety of the combination of omacetaxine and decitabine and to find the best dose to give to future patients. The goal ... Associated Drug(s):  Decitabine Phase:  ...

    Clinical Trial last updated 04/29/2016 - 11:19am.

  7. Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

    ... I/II trial studies the side effects and best dose of decitabine followed by mitoxantrone hydrochloride, etoposide, and ... as mitoxantrone hydrochloride, etoposide, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either ...

    Clinical Trial last updated 04/28/2016 - 9:51am.

  8. Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

    ... and improving constitutional symptoms. Low dose decitabine has demonstrated depletion of DNMT1 in normal hematopoietic ... . Furthermore, the low toxicity associated with low dose decitabine would allow for more frequent (1 to 3 times weekly) administration ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.

  9. Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

    ... given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The ... to stop them from growing and repairing themselves. Decitabine is designed to damage the DNA of cells, which may cause cancer cells ...

    Clinical Trial last updated 04/29/2016 - 12:17pm.

  10. Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

    ... research study is to compare how 2 different drugs, decitabine and azacitidine , when given on a shorter than standard ... Azacitidine Decitabine Phase:  ...

    Clinical Trial last updated 04/28/2016 - 10:22am.